Genus revealed its first major acquisition under the leadership of Karim Bitar with the takeover of pig genetics rival Genetiporc, a deal which the group said would boost its position in the Americas.
UK-based Genus - whose growth in a global concern was fuelled by acquisitions of the likes of ABS Global in 1999 and Syngen International in 2005 under previous chief executive Richard Wood – said that it had bought Genetiporc for £24.8m.
The purchase of Genetiporc brings operations in Canada, where the business is based, Brazil, Mexico and the US, and represented an "excellent strategic fit" with Genus's existing businesses in those countries, said Mr Bitar.
The acquisition would strengthen "our market position in that geography" besides helping Genus give "customers around the world a wider and deeper genetic pool".
The deal represents the first sizeable acquisition for Genus since Mr Bitar became chief executive two years ago, with the most notable deals under his reign up to now two joint ventures in China, by far the biggest pork producing country and a key target market.
However, he has also prioritised the deepening of the group's offering by extending the range of genetics it can call upon.
The acquisition represents an "important step in the strategic growth and development of Genus as we focus on providing the very best genetics", Mr Bitar said.
The acquisition is being undertaken mostly directly by Genus itself, which will buy Genetiporc's North American and Mexican assets, which achieved breakeven in the year to June on revenues of $60m (£37.5m).
The Brazilian operation, which achieved a pre-tax profit of R$1.5m (£400,000) on revenues of R$19m, will be purchased by Agroceres, a Brazil-based joint venture in which Genus owns 49%.
Genus's outlays comprise £18.8m for the equity in the North American and Mexican operations, plus £3.5m in debt, as well as £2.6m for its share of the Brazilian operation, totalling £24.9m, adjusted for rounding errors.
The group aims it will reap deal benefits, from factors such as cutting out duplicated costs, of £6.9m a year.
It is purchasing Genetiporc from Aliments Breton Foods, and eggs-to-feed group which has agreed for its pig production operations to buy genetics exclusively from Genus.